Zomedica Secures CE Mark for TRUFORMA Diagnostic Platform

Zomedica Corp. (NYSE American:ZOM), a veterinary health company, has obtained the CE mark for its point-of-care TRUFORMA Bulk Acoustic Wave (BAW) diagnostic platform. This certification ensures compliance with European Union safety, health, and environmental standards, allowing the platform's launch across the European Economic Area (EEA).

CEO Larry Heaton highlighted the significance of this milestone since the TRUFORMA system's initial U.S. launch in 2021. The platform provides fully quantitative results quickly, aiding veterinarians in making more confident treatment decisions.

Senior Product Manager Mike Mockler noted that the platform offers proprietary assays, such as the Cobalamin & Folate multiplex assay, providing unprecedented diagnostic capabilities at the point of care. Senior Director Brandon Marino emphasized the global impact, expecting better patient outcomes with faster decision-making enabled by TRUFORMA.

The potential market for TRUFORMA is substantial, with an annual recurring revenue opportunity of $1.5 billion in the U.S. and a European market forecasted to exceed $3.6 billion by 2028.